25 XP   0   0   10

Gain Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Gain Therapeutics Inc together

PenkeI guess you are interested in Gain Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Gain Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Gain Therapeutics Inc

I send you an email if I find something interesting about Gain Therapeutics Inc.

Quick analysis of Gain Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Gain Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.78
Expected worth in 1 year
$0.39
How sure are you?
12.0%

+ What do you gain per year?

Total Gains per Share
$-0.39
Return On Investment
-12.2%

For what price can you sell your share?

Current Price per Share
$3.19
Expected price per share
$2.9 - $4.04
How sure are you?
50%

1. Valuation of Gain Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$3.19

Intrinsic Value Per Share

$-19.61 - $-23.21

Total Value Per Share

$-18.83 - $-22.43

2. Growth of Gain Therapeutics Inc (5 min.)




Is Gain Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$12.5m$25m-$13.5m-117.6%

How much money is Gain Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$5.5m-$4.3m-$1.1m-21.0%
Net Profit Margin-2,327.5%-3,988.8%--

How much money comes from the company's main activities?

3. Financial Health of Gain Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#647 / 1010

Most Revenue
#687 / 1010

Most Profit
#450 / 1010

Most Efficient
#858 / 1010

What can you expect buying and holding a share of Gain Therapeutics Inc? (5 min.)

Welcome investor! Gain Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Gain Therapeutics Inc.

What can you expect buying and holding a share of Gain Therapeutics Inc?

First you should know what it really means to hold a share of Gain Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Gain Therapeutics Inc is $3.19. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Gain Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Gain Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.78. Based on the TTM, the Book Value Change Per Share is $-0.10 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Gain Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.29-9.1%-0.34-10.8%-0.27-8.5%-0.18-5.8%-0.15-4.7%
Usd Book Value Change Per Share0.3210.1%-0.10-3.1%-0.25-7.7%0.041.2%0.031.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.3210.1%-0.10-3.1%-0.25-7.7%0.041.2%0.031.0%
Usd Price Per Share3.27-3.96-3.52-3.39-2.71-
Price to Earnings Ratio-2.80--2.94--3.38--3.73--2.99-
Price-to-Total Gains Ratio10.09--10.71--14.95--17.72--17.72-
Price to Book Ratio4.21-5.79-2.31-2.37-1.90-
Price-to-Total Gains Ratio10.09--10.71--14.95--17.72--17.72-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.19
Number of shares313
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.100.04
Usd Total Gains Per Share-0.100.04
Gains per Quarter (313 shares)-30.4712.25
Gains per Year (313 shares)-121.8649.02
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-122-13204939
20-244-25409888
30-366-3760147137
40-487-4980196186
50-609-6200245235
60-731-7420294284
70-853-8640343333
80-975-9860392382
90-1097-11080441431
100-1219-12300490480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.025.00.00.0%0.025.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%3.010.07.015.0%3.011.011.012.0%3.011.011.012.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.025.00.0%0.00.025.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%3.010.07.015.0%3.011.011.012.0%3.011.011.012.0%

Fundamentals of Gain Therapeutics Inc

About Gain Therapeutics Inc

Gain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Fundamental data was last updated by Penke on 2024-04-11 09:40:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Gain Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Gain Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Gain Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Gain Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,327.5%+2,327.5%
TTM-2,327.5%YOY-3,988.8%+1,661.3%
TTM-2,327.5%5Y-8,243.5%+5,916.0%
5Y-8,243.5%10Y-7,665.5%-578.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM-2,327.5%-216.8%-2,110.7%
YOY-3,988.8%-288.3%-3,700.5%
5Y-8,243.5%-449.1%-7,794.4%
10Y-7,665.5%-605.5%-7,060.0%
1.1.2. Return on Assets

Shows how efficient Gain Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Gain Therapeutics Inc to the Biotechnology industry mean.
  • -25.4% Return on Assets means that Gain Therapeutics Inc generated $-0.25 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Gain Therapeutics Inc:

  • The MRQ is -25.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -31.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.4%TTM-31.3%+5.9%
TTM-31.3%YOY-15.0%-16.2%
TTM-31.3%5Y-141.3%+110.0%
5Y-141.3%10Y-126.3%-15.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.4%-13.3%-12.1%
TTM-31.3%-12.8%-18.5%
YOY-15.0%-11.7%-3.3%
5Y-141.3%-13.9%-127.4%
10Y-126.3%-15.7%-110.6%
1.1.3. Return on Equity

Shows how efficient Gain Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Gain Therapeutics Inc to the Biotechnology industry mean.
  • -37.6% Return on Equity means Gain Therapeutics Inc generated $-0.38 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Gain Therapeutics Inc:

  • The MRQ is -37.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -51.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-37.6%TTM-51.3%+13.7%
TTM-51.3%YOY-18.5%-32.8%
TTM-51.3%5Y-17.1%-34.2%
5Y-17.1%10Y-13.7%-3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-37.6%-16.9%-20.7%
TTM-51.3%-16.1%-35.2%
YOY-18.5%-15.1%-3.4%
5Y-17.1%-19.3%+2.2%
10Y-13.7%-20.2%+6.5%

1.2. Operating Efficiency of Gain Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Gain Therapeutics Inc is operating .

  • Measures how much profit Gain Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Gain Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Gain Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,369.4%+2,369.4%
TTM-2,369.4%YOY-4,001.3%+1,631.9%
TTM-2,369.4%5Y-8,137.9%+5,768.5%
5Y-8,137.9%10Y-7,572.8%-565.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM-2,369.4%-232.5%-2,136.9%
YOY-4,001.3%-298.2%-3,703.1%
5Y-8,137.9%-492.1%-7,645.8%
10Y-7,572.8%-632.4%-6,940.4%
1.2.2. Operating Ratio

Measures how efficient Gain Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Gain Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM24.031-24.031
TTM24.031YOY40.593-16.562
TTM24.0315Y66.791-42.759
5Y66.79110Y47.325+19.466
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM24.0313.310+20.721
YOY40.5933.890+36.703
5Y66.7915.739+61.052
10Y47.3257.876+39.449

1.3. Liquidity of Gain Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Gain Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.59 means the company has $3.59 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Gain Therapeutics Inc:

  • The MRQ is 3.592. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.184. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.592TTM3.184+0.408
TTM3.184YOY6.735-3.551
TTM3.1845Y5.536-2.353
5Y5.53610Y4.449+1.088
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5923.890-0.298
TTM3.1844.173-0.989
YOY6.7355.344+1.391
5Y5.5366.126-0.590
10Y4.4496.448-1.999
1.3.2. Quick Ratio

Measures if Gain Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Gain Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.45 means the company can pay off $4.45 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Gain Therapeutics Inc:

  • The MRQ is 4.452. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.611. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.452TTM4.611-0.159
TTM4.611YOY8.579-3.968
TTM4.6115Y6.070-1.459
5Y6.07010Y4.858+1.212
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4523.514+0.938
TTM4.6113.998+0.613
YOY8.5795.380+3.199
5Y6.0706.105-0.035
10Y4.8586.404-1.546

1.4. Solvency of Gain Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Gain Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Gain Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.32 means that Gain Therapeutics Inc assets are financed with 32.4% credit (debt) and the remaining percentage (100% - 32.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Gain Therapeutics Inc:

  • The MRQ is 0.324. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.372. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.324TTM0.372-0.048
TTM0.372YOY0.181+0.191
TTM0.3725Y0.736-0.364
5Y0.73610Y0.656+0.080
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3240.339-0.015
TTM0.3720.336+0.036
YOY0.1810.271-0.090
5Y0.7360.366+0.370
10Y0.6560.389+0.267
1.4.2. Debt to Equity Ratio

Measures if Gain Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Gain Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 47.9% means that company has $0.48 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Gain Therapeutics Inc:

  • The MRQ is 0.479. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.614. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.479TTM0.614-0.135
TTM0.614YOY0.222+0.392
TTM0.6145Y0.216+0.398
5Y0.21610Y0.173+0.043
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4790.388+0.091
TTM0.6140.402+0.212
YOY0.2220.335-0.113
5Y0.2160.426-0.210
10Y0.1730.461-0.288

2. Market Valuation of Gain Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Gain Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Gain Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -2.80 means the investor is paying $-2.80 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Gain Therapeutics Inc:

  • The EOD is -2.736. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.800. Based on the earnings, the company is expensive. -2
  • The TTM is -2.944. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.736MRQ-2.800+0.064
MRQ-2.800TTM-2.944+0.143
TTM-2.944YOY-3.384+0.440
TTM-2.9445Y-3.733+0.789
5Y-3.73310Y-2.986-0.747
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.736-2.264-0.472
MRQ-2.800-2.629-0.171
TTM-2.944-2.680-0.264
YOY-3.384-4.145+0.761
5Y-3.733-6.257+2.524
10Y-2.986-6.254+3.268
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Gain Therapeutics Inc:

  • The EOD is -2.283. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.337. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.478. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.283MRQ-2.337+0.054
MRQ-2.337TTM-3.478+1.141
TTM-3.478YOY-4.198+0.720
TTM-3.4785Y-4.167+0.689
5Y-4.16710Y-3.333-0.833
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.283-2.973+0.690
MRQ-2.337-3.333+0.996
TTM-3.478-3.553+0.075
YOY-4.198-5.605+1.407
5Y-4.167-8.376+4.209
10Y-3.333-8.865+5.532
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Gain Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.21 means the investor is paying $4.21 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Gain Therapeutics Inc:

  • The EOD is 4.110. Based on the equity, the company is fair priced.
  • The MRQ is 4.207. Based on the equity, the company is fair priced.
  • The TTM is 5.789. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.110MRQ4.207-0.097
MRQ4.207TTM5.789-1.582
TTM5.789YOY2.314+3.475
TTM5.7895Y2.375+3.414
5Y2.37510Y1.900+0.475
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.1101.896+2.214
MRQ4.2072.115+2.092
TTM5.7892.093+3.696
YOY2.3142.884-0.570
5Y2.3753.542-1.167
10Y1.9003.916-2.016
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Gain Therapeutics Inc.

3.1. Institutions holding Gain Therapeutics Inc

Institutions are holding 10.341% of the shares of Gain Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Greenlight Capital, Inc3.63230.093858841000
2023-12-31Royal Bank of Canada1.23610.0002200248-9752-4.6438
2023-12-31Geode Capital Management, LLC0.93510.000115147600
2023-12-31CM Management, LLC0.55560.23629000000
2023-12-31Vanguard Group Inc0.54560883851810525.7612
2023-12-31Springbok Capital Management, LLC0.35870.01265810000
2023-12-31Bridgeway Capital Management, LLC0.28460.00324610000
2023-09-30Citadel Advisors Llc0.2832045876962926.565
2023-12-31Northern Trust Corp0.268604351330236227.7322
2023-12-31Renaissance Technologies Corp0.26420.000242800-4100-8.742
2023-12-31Susquehanna International Group, LLP0.213034500-30726-47.107
2023-12-31BlackRock Inc0.1704027611-314-1.1244
2023-12-31Raymond James & Associates0.14680.000123788-10012-29.6213
2023-12-31Dimensional Fund Advisors, Inc.0.0981015886-933-5.5473
2023-12-31UBS Group AG0.0866014023571968.8704
2023-12-31Millennium Management LLC0.0788012764127640
2023-12-31XTX Topco Ltd0.07070.008211453114530
2023-12-31Advisor Group Holdings, Inc.0.06170.00011000000
2023-12-31Tower Research Capital LLC0.03020.00024892202270.453
2023-12-31Creekmur Asset Management LLC0.02740.0045444044400
Total 9.34770.35941514265+38531+2.5%

3.2. Funds holding Gain Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.48950.0004793955250.6657
2024-02-29Fidelity Total Market Index0.45220.00047333800
2024-02-29Fidelity Extended Market Index0.32590.000652852-256-0.482
2023-12-31Bridgeway Ultra-Small Company Market0.28420.0814610000
2024-03-31BlackRock Extended Equity Market K0.22560.00136584365840
2024-03-28iShares Micro-Cap ETF0.18450.01232992300
2024-02-29Fidelity Series Total Market Index0.0770.00011249600
2024-02-29Fidelity Nasdaq Composite Index0.0620.00031006200
2024-02-29Vanguard U.S. Eq Idx £ Acc0.05870.0002951500
2023-12-31Northern Trust Extended Eq Market Idx0.0520.0005842700
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0520.0005842700
2024-02-29Schwab Total Stock Market Index0.04340.0001704300
2024-02-29Spartan Total Market Index Pool E0.03940.0001638500
2024-03-31Extended Equity Market Fund M0.02780.001451345130
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.02540.0002411900
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.02040.0002330860.1817
2024-02-29Spartan Extended Market Index Pool E0.01220.0004198425614.8148
2024-02-291290 VT Micro Cap K0.01190.0059192500
2024-03-31State St US Extended Mkt Indx NL Cl C0.00990.0003160000
2023-12-31SSgA U.S. Extended Market Index Class I0.00990.0002160000
Total 2.46390.1057399596+41628+10.4%

3.3. Insider Transactions

Insiders are holding 16.179% of the shares of Gain Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-28Jeffrey Scott RileyBUY300003.86
2023-12-21Matthias AlderSELL2062.46

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Gain Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.324-0.097+130%-0.246+176%0.039+726%0.031+942%
Book Value Per Share--0.7760.712+9%1.549-50%0.957-19%0.766+1%
Current Ratio--3.5923.184+13%6.735-47%5.536-35%4.449-19%
Debt To Asset Ratio--0.3240.372-13%0.181+79%0.736-56%0.656-51%
Debt To Equity Ratio--0.4790.614-22%0.222+116%0.216+122%0.173+177%
Dividend Per Share----0%-0%-0%-0%
Eps---0.291-0.344+18%-0.271-7%-0.184-37%-0.151-48%
Free Cash Flow Per Share---0.349-0.291-17%-0.229-35%-0.158-55%-0.129-63%
Free Cash Flow To Equity Per Share--0.241-0.096+140%-0.230+195%0.179+34%0.144+67%
Gross Profit Margin--1.0031.001+0%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---23.208--------
Intrinsic Value_10Y_min---19.607--------
Intrinsic Value_1Y_max---1.150--------
Intrinsic Value_1Y_min---1.129--------
Intrinsic Value_3Y_max---4.352--------
Intrinsic Value_3Y_min---4.137--------
Intrinsic Value_5Y_max---8.634--------
Intrinsic Value_5Y_min---7.936--------
Market Cap51676086.000-2%52914806.93564175814.734-18%57021888.000-7%54852356.697-4%43881885.357+21%
Net Profit Margin----23.2750%-39.8880%-82.4350%-76.6550%
Operating Margin----23.6940%-40.0130%-81.3790%-75.7280%
Operating Ratio---24.031-100%40.593-100%66.791-100%47.325-100%
Pb Ratio4.110-2%4.2075.789-27%2.314+82%2.375+77%1.900+121%
Pe Ratio-2.736+2%-2.800-2.944+5%-3.384+21%-3.733+33%-2.986+7%
Price Per Share3.190-2%3.2653.961-18%3.520-7%3.386-4%2.709+21%
Price To Free Cash Flow Ratio-2.283+2%-2.337-3.478+49%-4.198+80%-4.167+78%-3.333+43%
Price To Total Gains Ratio9.858-2%10.090-10.711+206%-14.953+248%-17.720+276%-17.720+276%
Quick Ratio--4.4524.611-3%8.579-48%6.070-27%4.858-8%
Return On Assets---0.254-0.313+23%-0.150-41%-1.413+457%-1.263+398%
Return On Equity---0.376-0.513+37%-0.185-51%-0.171-55%-0.137-64%
Total Gains Per Share--0.324-0.097+130%-0.246+176%0.039+726%0.031+942%
Usd Book Value--12578224.00011535163.750+9%25096680.250-50%15507890.600-19%12401813.920+1%
Usd Book Value Change Per Share--0.324-0.097+130%-0.246+176%0.039+726%0.031+942%
Usd Book Value Per Share--0.7760.712+9%1.549-50%0.957-19%0.766+1%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.291-0.344+18%-0.271-7%-0.184-37%-0.151-48%
Usd Free Cash Flow---5660398.000-4720307.750-17%-3702773.000-35%-2558690.150-55%-2095874.480-63%
Usd Free Cash Flow Per Share---0.349-0.291-17%-0.229-35%-0.158-55%-0.129-63%
Usd Free Cash Flow To Equity Per Share--0.241-0.096+140%-0.230+195%0.179+34%0.144+67%
Usd Market Cap51676086.000-2%52914806.93564175814.734-18%57021888.000-7%54852356.697-4%43881885.357+21%
Usd Price Per Share3.190-2%3.2653.961-18%3.520-7%3.386-4%2.709+21%
Usd Profit---4723969.000-5566880.000+18%-4397684.500-7%-2984060.288-37%-2453404.280-48%
Usd Revenue---13795.000-100%70054.000-100%27669.038-100%23372.600-100%
Usd Total Gains Per Share--0.324-0.097+130%-0.246+176%0.039+726%0.031+942%
 EOD+2 -6MRQTTM+22 -10YOY+10 -225Y+12 -2010Y+17 -15

4.2. Fundamental Score

Let's check the fundamental score of Gain Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.736
Price to Book Ratio (EOD)Between0-14.110
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.452
Current Ratio (MRQ)Greater than13.592
Debt to Asset Ratio (MRQ)Less than10.324
Debt to Equity Ratio (MRQ)Less than10.479
Return on Equity (MRQ)Greater than0.15-0.376
Return on Assets (MRQ)Greater than0.05-0.254
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Gain Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.657
Ma 20Greater thanMa 503.426
Ma 50Greater thanMa 1004.055
Ma 100Greater thanMa 2003.678
OpenGreater thanClose3.540
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets18,609
Total Liabilities6,031
Total Stockholder Equity12,578
 As reported
Total Liabilities 6,031
Total Stockholder Equity+ 12,578
Total Assets = 18,609

Assets

Total Assets18,609
Total Current Assets17,779
Long-term Assets830
Total Current Assets
Cash And Cash Equivalents 11,795
Short-term Investments 5,000
Net Receivables 243
Other Current Assets 742
Total Current Assets  (as reported)17,779
Total Current Assets  (calculated)17,779
+/-0
Long-term Assets
Property Plant Equipment 585
Intangible Assets 193
Long-term Assets Other 18
Long-term Assets  (as reported)830
Long-term Assets  (calculated)796
+/- 34

Liabilities & Shareholders' Equity

Total Current Liabilities4,950
Long-term Liabilities1,081
Total Stockholder Equity12,578
Total Current Liabilities
Short-term Debt 348
Short Long Term Debt 119
Accounts payable 1,319
Other Current Liabilities 2,160
Total Current Liabilities  (as reported)4,950
Total Current Liabilities  (calculated)3,947
+/- 1,003
Long-term Liabilities
Long term Debt 449
Capital Lease Obligations 460
Long-term Liabilities  (as reported)1,081
Long-term Liabilities  (calculated)909
+/- 173
Total Stockholder Equity
Common Stock2
Retained Earnings -60,784
Accumulated Other Comprehensive Income 247
Other Stockholders Equity 73,113
Total Stockholder Equity (as reported)12,578
Total Stockholder Equity (calculated)12,578
+/-0
Other
Capital Stock2
Cash and Short Term Investments 16,795
Common Stock Shares Outstanding 16,207
Current Deferred Revenue1,122
Liabilities and Stockholders Equity 18,609
Net Debt -10,768
Net Invested Capital 13,146
Net Working Capital 12,829
Property Plant and Equipment Gross 678
Short Long Term Debt Total 1,027



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
> Total Assets 
0
0
0
0
165
165
165
165
0
0
0
0
9,604
48,041
45,353
42,562
38,985
37,599
31,890
28,326
24,099
21,323
18,261
14,097
18,609
18,60914,09718,26121,32324,09928,32631,89037,59938,98542,56245,35348,0419,60400001651651651650000
   > Total Current Assets 
0
0
0
0
107
107
107
107
430
0
0
0
8,988
47,384
44,335
41,555
37,722
36,392
25,833
24,349
21,091
19,322
17,308
13,242
17,779
17,77913,24217,30819,32221,09124,34925,83336,39237,72241,55544,33547,3848,9880004301071071071070000
       Cash And Cash Equivalents 
0
0
0
0
76
76
76
76
0
0
0
0
7,493
46,594
43,163
40,979
36,881
34,339
14,306
10,880
7,312
5,988
6,320
4,273
11,795
11,7954,2736,3205,9887,31210,88014,30634,33936,88140,97943,16346,5947,4930000767676760000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,939
11,851
12,827
11,828
9,873
7,960
5,000
5,0007,9609,87311,82812,82711,8519,939000000000000000000
       Net Receivables 
0
0
0
0
11
11
11
11
45
0
0
0
67
71
450
99
114
216
132
168
191
137
161
102
243
24310216113719116813221611499450716700045111111110000
       Other Current Assets 
0
0
0
0
0
20
20
20
81
0
0
0
1,439
719
722
477
841
1,837
1,456
1,450
953
1,369
1,115
907
742
7429071,1151,3699531,4501,4561,8378414777227191,4390008120202000000
   > Long-term Assets 
0
0
0
0
58
58
58
58
0
0
0
0
617
657
1,018
1,008
1,263
1,207
6,057
3,976
3,008
2,001
952
856
830
8308569522,0013,0083,9766,0571,2071,2631,0081,0186576170000585858580000
       Property Plant Equipment 
0
0
0
0
55
55
55
55
219
0
0
0
553
554
887
851
1,007
938
885
807
804
755
698
618
585
5856186987558048078859381,007851887554553000219555555550000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,918
2,916
1,941
988
0
0
0
0009881,9412,9164,918000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
39
203
221
208
208
214
209
205
189
193
19318920520921420820822120339000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
11
0
0
0
64
103
111
118
53
48
46
45
48
0
50
0
0
005004845464853118111103640001100000000
> Total Liabilities 
0
0
0
0
278
278
278
278
0
0
0
0
3,402
3,577
3,964
5,017
4,168
5,771
4,873
5,663
5,220
6,184
7,168
6,767
6,031
6,0316,7677,1686,1845,2205,6634,8735,7714,1685,0173,9643,5773,40200002782782782780000
   > Total Current Liabilities 
0
0
0
0
220
220
220
220
879
0
0
0
2,115
2,327
2,451
3,577
2,553
4,217
3,410
4,332
4,125
5,155
5,588
5,763
4,950
4,9505,7635,5885,1554,1254,3323,4104,2172,5533,5772,4512,3272,1150008792202202202200000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
145
166
247
257
323
309
300
316
337
342
347
340
348
348340347342337316300309323257247166145000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
23
44
65
87
104
87
84
101
108
109
112
109
119
119109112109108101848710487654423000000000000
       Accounts payable 
0
0
0
0
0
39
39
39
154
0
0
0
962
882
978
789
560
2,118
949
1,019
1,626
2,213
924
1,377
1,319
1,3191,3779242,2131,6261,0199492,11856078997888296200015439393900000
       Other Current Liabilities 
0
0
0
0
0
89
89
89
372
0
0
0
768
1,101
855
2,203
1,403
1,587
2,081
2,942
2,107
2,600
3,247
2,693
2,160
2,1602,6933,2472,6002,1072,9422,0811,5871,4032,2038551,10176800037289898900000
   > Long-term Liabilities 
0
0
0
0
58
58
58
58
0
0
0
0
1,288
1,250
1,513
1,440
1,615
1,554
1,463
1,331
1,095
1,029
1,580
1,003
1,081
1,0811,0031,5801,0291,0951,3311,4631,5541,6151,4401,5131,2501,2880000585858580000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
495
478
467
0
0
0046747849500000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
132
0
0
0
172
194
236
244
329
367
376
378
158
0
783
0
0
00783015837837636732924423619417200013200000000
> Total Stockholder Equity
0
0
0
0
0
-112
-112
-112
0
0
0
0
6,202
44,464
41,389
37,545
34,818
31,828
27,017
22,663
18,880
15,139
11,093
7,331
12,578
12,5787,33111,09315,13918,88022,66327,01731,82834,81837,54541,38944,4646,2020000-112-112-11200000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
2
2111111111110000000000000
   Retained Earnings Total Equity000-38,516-20,92500000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-1
-1
-1
-1
0
0
0
0
-153
-157
-164
-112
-91
-114
-146
-297
36
96
134
91
247
247911349636-297-146-114-91-112-164-157-1530000-1-1-1-10000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
57,359
58,695
62,299
0
0
0062,29958,69557,35900000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
753
753
753
-81
0
0
0
13,389
54,105
54,594
55,362
41,851
56,139
56,445
56,800
57,359
58,695
49,473
45,755
73,113
73,11345,75549,47358,69557,35956,80056,44556,13941,85155,36254,59454,10513,389000-8175375375300000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue55
Cost of Revenue-80
Gross Profit-25-25
 
Operating Income (+$)
Gross Profit-25
Operating Expense-22,228
Operating Income-22,253-22,253
 
Operating Expense (+$)
Research Development11,486
Selling General Administrative10,788
Selling And Marketing Expenses46
Operating Expense22,22822,319
 
Net Interest Income (+$)
Interest Income494
Interest Expense-0
Other Finance Cost-58
Net Interest Income552
 
Pretax Income (+$)
Operating Income-22,253
Net Interest Income552
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-22,188-22,318
EBIT - interestExpense = -22,253
-22,188
-22,268
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-22,253-22,188
Earnings Before Interest and Taxes (EBITDA)-22,173
 
After tax Income (+$)
Income Before Tax-22,188
Tax Provision-143
Net Income From Continuing Ops-22,218-22,331
Net Income-22,268
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses22,308
Total Other Income/Expenses Net65-552
 

Technical Analysis of Gain Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Gain Therapeutics Inc. The general trend of Gain Therapeutics Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Gain Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Gain Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 3.55 < 4.04 < 4.04.

The bearish price targets are: 2.95 > 2.925 > 2.9.

Tweet this
Gain Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Gain Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Gain Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Gain Therapeutics Inc. The current macd is -0.24063542.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Gain Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Gain Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Gain Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Gain Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartGain Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Gain Therapeutics Inc. The current adx is 37.87.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Gain Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Gain Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Gain Therapeutics Inc. The current sar is 2.97900767.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Gain Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Gain Therapeutics Inc. The current rsi is 36.66. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Gain Therapeutics Inc Daily Relative Strength Index (RSI) ChartGain Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Gain Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Gain Therapeutics Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Gain Therapeutics Inc Daily Stochastic Oscillator ChartGain Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Gain Therapeutics Inc. The current cci is -30.74976259.

Gain Therapeutics Inc Daily Commodity Channel Index (CCI) ChartGain Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Gain Therapeutics Inc. The current cmo is -24.32212309.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Gain Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartGain Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Gain Therapeutics Inc. The current willr is -66.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Gain Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Gain Therapeutics Inc Daily Williams %R ChartGain Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Gain Therapeutics Inc.

Gain Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Gain Therapeutics Inc. The current atr is 0.30978908.

Gain Therapeutics Inc Daily Average True Range (ATR) ChartGain Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Gain Therapeutics Inc. The current obv is 5,741,130.

Gain Therapeutics Inc Daily On-Balance Volume (OBV) ChartGain Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Gain Therapeutics Inc. The current mfi is 39.78.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Gain Therapeutics Inc Daily Money Flow Index (MFI) ChartGain Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Gain Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Gain Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Gain Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.657
Ma 20Greater thanMa 503.426
Ma 50Greater thanMa 1004.055
Ma 100Greater thanMa 2003.678
OpenGreater thanClose3.540
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Gain Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Gain Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Gain Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Gain Therapeutics Inc

I send you an email if I find something interesting about Gain Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Gain Therapeutics Inc.

Receive notifications about Gain Therapeutics Inc in your mailbox!